510(k) Report

De Novo · Granted

Granted

Heartflow Ffrct

DEN130045De NovoGranted Nov 26, 2014387-day reviewClass II21 CFR 870.1415

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Heartflow · PJA Coronary Vascular Physiologic Simulation Software

Granted on Nov 26, 2014 as a new device type through De Novo after a 387-day review. 11 later devices descend from it.

Decided
Nov 26, 2014
Review
387 days
Class
Class II
Product code
PJA
Recalls
None

11 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2016: 2 descendants cleared2026: 1 descendant cleared2018: 2 descendants cleared2022: 2 descendants cleared2019: 2 descendants cleared2021: 1 descendant cleared2025: 1 descendant cleared2010201520202025
  1. This deviceDEN130045 Heartflow FfrctHeartflow · 2014
  2. Descendant · cites it directly · 9 of its ownK152733 FFRctHeartFlow, Inc. · 2016
  3. Descendant · 2 generations on · 8 of its ownK161772 FFRctHeartFlow, Inc. · 2016
  4. Descendant · 3 generations on · 4 of its ownK182035 FFRctHeartFlow, Inc. · 2018
  5. Descendant · 4 generations on · 3 of its ownK190925 HeartFlow FFRct AnalysisHeartFlow, Inc. · 2019
  6. Descendant · 5 generations on · 2 of its ownK203329 HeartFlow AnalysisHeartFlow, Inc. · 2021

Showing 5 of 11 descendants. See all descendants

Descendants cleared per year

2016: 22018: 22019: 22021: 12022: 22025: 12026: 1
2016high 2 (2016) · low 0 (2017)2026

Most influential descendants

Showing 5 of 11 · See all
  • K152733FFRctHeartFlow, Inc. · 2016 · cites it directly9descendants
  • K161772FFRctHeartFlow, Inc. · 2016 · 2 generations on8descendants
  • K182035FFRctHeartFlow, Inc. · 2018 · 3 generations on4descendants
  • K190925HeartFlow FFRct AnalysisHeartFlow, Inc. · 2019 · 4 generations on3descendants
  • K203329HeartFlow AnalysisHeartFlow, Inc. · 2021 · 5 generations on2descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN130045Heartflow FfrctHeartflow2014—
+1K152733FFRctHeartFlow, Inc.2016—
+2K161772FFRctHeartFlow, Inc.2016—
+3K182035FFRctHeartFlow, Inc.2018—
+4K190925HeartFlow FFRct AnalysisHeartFlow, Inc.2019—
+5K203329HeartFlow AnalysisHeartFlow, Inc.2021—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201620
201820
201920
202110
202220
202510
202610
FIG. 1 — Lineage of DEN130045, 2014–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PJA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PJA device

  1. #1 K250902 HeartFlow Analysisscore 13.0 · 12 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (11)

See all 11

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K152733FFRctHeartFlow, Inc.20169
K262015Elucid FFR-IQ (B.1)Elucid Bioimaging, Inc.20260

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K152733 (HeartFlow, Inc., 2016) has gone furthest, with 9 descendants of its own.

How does its category compare?

All PJA devices

PJA Coronary Vascular Physiologic Simulation Software: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · PJA

1in 2025

2014: 12016: 22018: 12019: 12021: 12022: 22025: 12026 (partial year): 1
2007high 2 (2016) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PJA

Too few PJA 510(k)s in any year since 2007 to give a median.

Recalls per year · PJA

No recall names PJA since 2007.

Adverse event reports per year · PJA

16in 2025

2017: 42018: 122019: 652020: 92021: 22022: 12023: 82024: 142025: 16
2007high 65 (2019) · low 0 (2007)2025

MAUDE reports naming product code PJA, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—00
20150—00
20162—00
20170—04
20181—012
20191—065
20200—09
20211—02
20222—01
20230—08
20240—014
20251—016
20261—0—

What is it indicated for?

HeartFlow FFRCT is a post-processing software for the clinical quantitative and qualitative analysis of previously acquired Computed Tomography (CT) DICOM data for clinically stable symptomatic patients with coronary artery disease. It provides FFRCT, a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images. FFRCT analysis is…

Read the full statement (130 words)

HeartFlow FFRCT is a post-processing software for the clinical quantitative and qualitative analysis of previously acquired Computed Tomography (CT) DICOM data for clinically stable symptomatic patients with coronary artery disease. It provides FFRCT, a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images. FFRCT analysis is intended to support the functional evaluation of coronary artery disease. The results of this analysis are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of HeartFlow FFRCT are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment. It is for prescription use only.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN130045: Heartflow Ffrct.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN130045

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026